Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Beltrame

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
BMC Cancer|May 27, 2017
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosisLaura Zanotti, Chiara Romani, Laura Tassone, et al.
Cells|December 7, 2019
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric StudyEnrica Calura, Matteo Ciciani, Andrea Sambugaro, et al.
Neurobiology of Disease|August 6, 2022
Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsyAlessia Salamone, Gaetano Terrone, Rossella Di Sapia, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2022
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosisChiara Pesenti, Luca Beltrame, Angelo Velle, et al.
Blood|August 21, 2013
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting TregAndreas S Baur, Manfred B Lutz, Stephan Schierer, et al.
Cancer Letters|December 27, 2016
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohortsPaola Todeschini, Elisa Salviato, Lara Paracchini, et al.
The Journal of Pathology|October 26, 2018
Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomesMaria Antonia Frassanito, Vanessa Desantis, Lucia Di Marzo, et al.
International Journal of Cancer|October 17, 2024
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 studyEliana Bignotti, Vittorio Simeon, Laura Ardighieri, et al.
Science Translational Medicine|December 6, 2023
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancerLara Paracchini, Laura Mannarino, Chiara Romualdi, et al.
International Journal of Cancer|March 21, 2019
Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3Sara Ballabio, Ilaria Craparotta, Lara Paracchini, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
BMC Cancer|May 27, 2017
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosisLaura Zanotti, Chiara Romani, Laura Tassone, et al.
Cells|December 7, 2019
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric StudyEnrica Calura, Matteo Ciciani, Andrea Sambugaro, et al.
Neurobiology of Disease|August 6, 2022
Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsyAlessia Salamone, Gaetano Terrone, Rossella Di Sapia, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2022
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosisChiara Pesenti, Luca Beltrame, Angelo Velle, et al.
Blood|August 21, 2013
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting TregAndreas S Baur, Manfred B Lutz, Stephan Schierer, et al.
Cancer Letters|December 27, 2016
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohortsPaola Todeschini, Elisa Salviato, Lara Paracchini, et al.
The Journal of Pathology|October 26, 2018
Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomesMaria Antonia Frassanito, Vanessa Desantis, Lucia Di Marzo, et al.
International Journal of Cancer|October 17, 2024
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 studyEliana Bignotti, Vittorio Simeon, Laura Ardighieri, et al.
Science Translational Medicine|December 6, 2023
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancerLara Paracchini, Laura Mannarino, Chiara Romualdi, et al.
International Journal of Cancer|March 21, 2019
Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3Sara Ballabio, Ilaria Craparotta, Lara Paracchini, et al.
Pageof 6